Presentation is loading. Please wait.

Presentation is loading. Please wait.

Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136.

Published byJeffry Watson Modified over 9 years ago

Similar presentations

Presentation on theme: "Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136."— Presentation transcript:

1 Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

2 Classes of recommendations Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

3 Levels of evidence Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

4 Investigational algorithm for patients with coronary artery disease and diabetes mellitus Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

5 Definition, classification, and screening of diabetes and pre-diabetic glucose abnormalities Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

6 Criteria used for glucometabolic classification according to the WHO (1999) and ADA (1997 and 2003) (values are expressed as venous plasma glucose) Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

7 Aetiological classification of glycaemia disordersa a Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

8 Conversion factors between plasma and other vehicles for glucose values Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

9 Fasting and post-load glucose levels identify different individuals with asymptomatic diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

10 FINnish Diabetes Risk SCore (FINDRISC) to assess the 10 year risk of type 2 diabetes in adults Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

11 Epidemiology of diabetes, IGH, and cardiovascular risk Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

12 Age- and gender-specific prevalence of diabetes in 13 European population-based cohorts included in the DECODE study Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

13 Identification of subjects at high risk for CVD or diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

14 Summary of the findings of four lifestyle intervention studies that aimed at preventing type 2 diabetes in subjects with IGT Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

15 Treatment to reduce cardiovascular risk Lifestyle and comprehensive management Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

16 Mean efficacy of pharmacological treatment options in patients with type 2 diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

17 Percentage of patients achieving pre-defined intensive treatment targets in the Steno 2 study Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

18 Glycaemic targets for the care of patients with diabetes as recommended by various organizations Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

19 Potential downsides of pharmacological treatment modalities in patients with type 2 diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

20 Suggested policy for the selection of glucose- lowering therapy according to the glucometabolic situation Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

21 Treatment to reduce cardiovascular risk - Dyslipidaemia Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

22 Subgroups of patients with DM in the major secondary prevention trials with statins and the proportionate risk reduction in patients with and without diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

23 Treatment to reduce cardiovascular risk - Blood pressure Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

24 Treatment effects of antihypertensive drugs in comparison with placebo or less intensive treatment as reported in randomized clinical trials Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

25 Treatment effects expressed in hazard ratios (95% CI) in randomized clinical trials comparing different antihypertensive treatments in hypertensive patients with type 2 diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

26 Management of CVD - Coronary artery disease Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

27 Treatment options based on accumulated evidence Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

28 Recommended treatment targets for patients with diabetes and CAD Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

29 Diabetes and coronary revascularization Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

30 Trials addressing diabetes and revascularization for multivessel disease Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

31 Revascularization in diabetes patients with multivessel disease in the stent-era Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

32 Heart failure and diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

33 Arrhythmias: atrial fibrillation and sudden cardiac death Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

34 Peripheral vascular disease Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

35 Investigations of the peripheral circulation in diabetic patients Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

36 Stroke Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

37 Intensive care Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

38 Published trials on intensive insulin therapy in critical illness Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

39 Health economics and diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

40 Direct medical costs for patients with type 2 diabetes in eight European countries and percentage of healthcare expenditure in the respective countries (1998) Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Download ppt "Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136."

Similar presentations

Summary Prepared by Melvyn Rubenfire, MD

Summary Prepared by Melvyn Rubenfire, MD
NCEP ATP IV GuidelineS: 2013 Update

NCEP ATP IV GuidelineS: 2013 Update
1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.

1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.

1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
Epidemiology of Peripheral Vascular Disease Sohail Ahmed School of Population and Health Sciences.

Epidemiology of Peripheral Vascular Disease Sohail Ahmed School of Population and Health Sciences.
CVD risk estimation and prevention: An overview of SIGN 97.

CVD risk estimation and prevention: An overview of SIGN 97.
Lipid Disorders and Management in Diabetes

Lipid Disorders and Management in Diabetes
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Benefits of intensive multiple risk factor intervention.

Benefits of intensive multiple risk factor intervention.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care

Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Cholesterol quintile (mg/dL)

Cholesterol quintile (mg/dL)
Diabetes Mellitus Type 2

Diabetes Mellitus Type 2
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
The concept of Diabetes & CV risk: A lifetime risk challenge Diabetes & CV Risk: Routine practice versus guidelines Eberhard Standl, MD Professor of Medicine.

The concept of Diabetes & CV risk: A lifetime risk challenge Diabetes & CV Risk: Routine practice versus guidelines Eberhard Standl, MD Professor of Medicine.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?

Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.

Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Epidemiology of Diabetes Mellitus by Santi Martini Departemen of Epidemiology Faculty of Public Health University of Airlangga.

Epidemiology of Diabetes Mellitus by Santi Martini Departemen of Epidemiology Faculty of Public Health University of Airlangga.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.

AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.

Similar presentations

Ads by Google